Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-07-18

FDA Approved: LAMOTRIGINE — Supplemental Application (Jubilant Cadista Pharmacuticals Inc.)

View source ↗

Summary

The FDA approved a supplemental application for a generic lamotrigine product from Jubilant Cadista Pharmaceuticals Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lamotrigine (lamotrigine)

Snippet

SUPPL AP for LAMOTRIGINE (LAMOTRIGINE)